Seeking partners such as NGOs, academic institutions, and companies to expand and accelerate our portfolio of drugs for neglected diseases, including emerging and tropical infectious diseases.

Charles Bailey
Novartis is uniquely diversified across therapy areas with exposure to cutting-edge technology platforms.
Looking for truly differentiating first or best-in-class treatments in:
Thierry Droz-Georget
Looking for truly differentiating first or best-in-class treatments in:
Dominic Ehrismann
Looking for truly differentiating first or best-in-class treatments in:
Chi-Chi Zhu
Looking for truly differentiating first or best-in-class treatments in:
Markus Werner
Looking for truly differentiating first or best-in-class treatments:
Markus Werner
Seeking transformative approaches to address genetic disease
Elizabeth Leshen
Seeking to develop and deliver life-changing medicines for diseases and conditions from front to back of the eye, enabled by data, transformative technologies, and partnerships.
Andreas Sailer
Interested in disease modifying treatments and renal indications with high unmet need.
Andreas Sailer
We accept that innovation happens outside of areas of interest- we are still prepared to discuss transformational areas we may have missed. We have a special team for you to talk with.
Andreas Sailer
Discovery platforms to drive target discovery and understanding of disease processes at the cell/gene level. This includes genome engineering, innovative data science approaches and prototyping novel paths to drug discovery at the interface of chemistry and biology.
Cynthia Hong
Seeking partners such as NGOs, academic institutions, and companies to expand and accelerate our portfolio of drugs for neglected diseases, including emerging and tropical infectious diseases.
Charles Bailey